Literature DB >> 25683471

Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia.

N Geevasinga1, P Menon, C M Sue, K R Kumar, K Ng, C Yiannikas, M C Kiernan, S Vucic.   

Abstract

BACKGROUND AND
PURPOSE: Cortical hyperexcitability has been identified as an important pathogenic mechanism in motor neuron disease (MND). The issue as to whether cortical hyperexcitability is a common process across the MND phenotypes, including amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS), remains unresolved. Separately, the clinical distinction between PLS and 'mimic disorders' such as hereditary spastic paraparesis (HSP) may be difficult, potentially delaying diagnosis. Consequently, the aim of the present study was to determine the nature and spectrum of cortical excitability changes across the MND phenotypes, and to determine whether the presence of cortical dysfunction distinguishes PLS from HSP.
METHODS: Cortical excitability studies were undertaken on a cohort of 14 PLS, 82 ALS and 13 HSP patients with mutations in the spastin gene.
RESULTS: Cortical hyperexcitability, as heralded by reduction of short interval intracortical inhibition (PLS 0.26%, -3.8% to 1.4%; ALS -0.15%, -3.6% to 7.0%; P < 0.01) and cortical silent period duration (CSPPLS 172.2 ± 5.4 ms; CSPALS 178.1 ± 5.1 ms; P < 0.001), along with an increase in intracortical facilitation was evident in ALS and PLS phenotypes, although appeared more frequently in ALS. Inexcitability of the motor cortex was more frequent in PLS (PLS 71%, ALS 24%, P < 0.0001). Cortical excitability was preserved in HSP.
CONCLUSIONS: Cortical dysfunction appears to be an intrinsic process across the MND phenotypes, with cortical inexcitability predominating in PLS and cortical hyperexcitability predominating in ALS. Importantly, cortical excitability was preserved in HSP, thereby suggesting that the presence of cortical dysfunction could help differentiate PLS from HSP in a clinical setting.
© 2015 EAN.

Entities:  

Keywords:  hereditary spastic paraplegia; motor neuron disease; neurological disorders; neuromuscular diseases; primary lateral sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25683471     DOI: 10.1111/ene.12669

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  20 in total

Review 1.  Primary Lateral Sclerosis.

Authors:  Jeffrey M Statland; Richard J Barohn; Mazen M Dimachkie; Mary Kay Floeter; Hiroshi Mitsumoto
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease.

Authors:  Steve Vucic; Matthew C Kiernan
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 3.  Pathophysiological and diagnostic implications of cortical dysfunction in ALS.

Authors:  Nimeshan Geevasinga; Parvathi Menon; P Hande Özdinler; Matthew C Kiernan; Steve Vucic
Journal:  Nat Rev Neurol       Date:  2016-09-23       Impact factor: 42.937

4.  Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis.

Authors:  Marco Pagani; Johanna Öberg; Fabrizio De Carli; Andrea Calvo; Cristina Moglia; Antonio Canosa; Flavio Nobili; Silvia Morbelli; Piercarlo Fania; Angelina Cistaro; Adriano Chiò
Journal:  Hum Brain Mapp       Date:  2015-12-24       Impact factor: 5.038

5.  Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Smriti Agarwal; Elizabeth Highton-Williamson; Jashelle Caga; José M Matamala; Thanuja Dharmadasa; James Howells; Margaret C Zoing; Kazumoto Shibuya; Nimeshan Geevasinga; Steve Vucic; John R Hodges; Rebekah M Ahmed; Matthew C Kiernan
Journal:  J Neurol       Date:  2018-06-04       Impact factor: 4.849

6.  Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial.

Authors:  Michael D Weiss; Eric A Macklin; Courtney E McIlduff; Steve Vucic; Brian J Wainger; Matthew C Kiernan; Stephen A Goutman; Namita A Goyal; Seward B Rutkove; Shafeeq S Ladha; I-Hweii Amy Chen; Matthew B Harms; Thomas H Brannagan; David Lacomis; Sasha Zivkovic; Maxwell Ma; Leo H Wang; Zachary Simmons; Michael H Rivner; Jeremy M Shefner; Merit E Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2020-12-31       Impact factor: 3.217

Review 7.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

8.  Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS.

Authors:  Barış Genç; Javier H Jara; Amiko K B Lagrimas; Peter Pytel; Raymond P Roos; M Marsel Mesulam; Changiz Geula; Eileen H Bigio; P Hande Özdinler
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

Review 9.  Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia.

Authors:  Timothy Fullam; Jeffrey Statland
Journal:  Brain Sci       Date:  2021-05-11

Review 10.  Cortical Excitability across the ALS Clinical Motor Phenotypes.

Authors:  Thanuja Dharmadasa
Journal:  Brain Sci       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.